Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alogliptin vs placebo in pediatric type 2 diabetes mellitus
2015-000208-25Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Alogliptin 25 mg once daily with Placebo once daily (2 arms). Primary endpoint: Primary: Change in HbA1c from baseline to Week 26. Started Aug 2017; status: completed.
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-000208-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000208-25.